Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stock Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

TCON news

TRACON Pharmaceuticals (NASDAQ:TCON) Stock Sees heavy Selling Pressure: Here is Why

Clinical stage biopharmaceutical company focusing on development and commercialisation of unique cancer therapeutics, TRACON Pharmaceuticals (NASDAQ:TCON), on 22nd July, 2021 announced that due to demand, underwriter has accepted on augmenting size of earlier announced public offering. TRACON said that purchase on a firm commitment basis 3,926,702 shares of common stock of firm at a price …

Continue reading “TRACON Pharmaceuticals (NASDAQ:TCON) Stock Sees heavy Selling Pressure: Here is Why”

Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
*By submitting your information you agree to the terms of our Privacy Policy. You will receive the DRP Journal newsletter, and third party offers. You can unsubscribe anytime by selecting unsubscribe at the bottom of our emails.